Precigen, Inc. (PGEN)

1,3593 +0,0093 (+0,69%) Ab 12:59PM EDT. Markt geöffnet.

Precigen, Inc.

20358 Seneca Meadows Parkway
Germantown, MD 20876
United States
301 556 9900
https://precigen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 202

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Randal J. Kirk J.D.	Executive Chairman	100k	N/A	1953
Dr. Helen Sabzevari MPH, Ph.D.	President, CEO & Director	1,02M	N/A	1962
Mr. Harry Thomasian Jr.	Chief Financial Officer	508,54k	N/A	1962
Mr. Rutul R. Shah	Chief Operating Officer	453,02k	N/A	1981
Mr. Donald P. Lehr	Chief Legal Officer & Corporate Secretary	618,32k	N/A	1975
Mr. Jeffrey Thomas Perez J.D.	Senior Vice President of Intellectual Property Affairs	540,67k	N/A	1972
Mr. Steven Harasym	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Rob Russell	VP & Head of Human Resources	N/A	N/A	N/A
Dr. Douglas E. Brough Ph.D.	Senior VP & Head of Research	N/A	N/A	1955
Dr. Bryan T. Butman Ph.D.	Senior VP & Head of CMC	N/A	N/A	1953

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Corporate Governance

Precigen, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 3, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.